A practitioner's toolkit for managing the menopause

Climacteric

Volumn 17, Issue 5, 2014, Pages 564-579

  Jane, F M ^a   Davis, S R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

menopause; postmenopausal hormone therapy

Indexed keywords

ANDROGEN; BAZEDOXIFENE; CLONIDINE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GABAPENTIN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; OSPEMIFENE; PRASTERONE; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TIBOLONE;

ACNE; ALGORITHM; ANDROGEN THERAPY; ARTICLE; BREAST TENDERNESS; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL EXAMINATION; CLITOROMEGALY; COGNITIVE THERAPY; CONSULTATION; DIZZINESS; DRUG MEGADOSE; EDEMA; HEADACHE; HEALTH CARE PERSONNEL; HIRSUTISM; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPNOSIS; LOW DRUG DOSE; MASTALGIA; MEDICAL HISTORY; MEDICAL SOCIETY; MENOPAUSAL SYNDROME; MENOPAUSE; MENORRHAGIA; MENTAL INSTABILITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NIGHT SWEAT; OBESITY; PATIENT CARE; PEER REVIEW; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); S; SOMNOLENCE; SPOTTING; STELLATE GANGLION BLOCK; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VIRILIZATION; XEROSTOMIA; ADULT; AGED; DIFFERENTIAL DIAGNOSIS; ESTROGEN THERAPY; EVIDENCE BASED PRACTICE; FEMALE; GENERAL PRACTITIONER; MIDDLE AGED; PRIMARY HEALTH CARE; WOMEN'S HEALTH;

ADULT; AGED; ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED PRACTICE; FEMALE; GENERAL PRACTITIONERS; HUMANS; MENOPAUSE; MIDDLE AGED; PRIMARY HEALTH CARE; SOCIETIES, MEDICAL; WOMEN'S HEALTH;

EID: 84907868517     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.929651     Document Type: Article

References (62)

1. Position statement: Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 25-54
2. de Villiers TJ, P ines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013; 16: 316-37
3. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010; 95(7 Suppl 1): S1-66
4. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 3697-710
5. National Institutes of Health State-of-The-Science Conference Statement: Management of menopause-related symptoms. Ann Intern Med 2005; 142: 1003-13
6. Bell RJ, Lijovic M, Fradkin P, Davis SR. A pragmatic approach to the classification of menopausal status for community-based research. Menopause 2008; 15: 978-83
7. Gold EB, Crawford SL, Avis NE, et al. Factors related to age at natural menopause: Longitudinal analyses from SWAN. Am J Epidemiol 2013; 178: 70-83
8. Qiu C, Chen H, Wen J, et al. Associations between age at menarche and menopause with cardiovascular disease, diabetes, and osteoporosis in Chinese women. J Clin Endocrinol Metab 2013; 98: 1612-21
9. Castelo-Branco C, Blumel J E, Chedraui P, et al. Age at menopause in Latin America. Menopause 2006; 13: 706-12
10. Harlow S D, Gass M, Hall J E, et al. Executive summary of the Stages of Reproductive Aging Workshop-10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97: 1159-68
11. Zumoff B, Strain G W, Miller L K, Rosner W. Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. 1995; 80: 1429-30
12. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-53
13. Burger H G, Dudley E C, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000; 85: 2832-8
14. Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974; 118: 793-8
15. van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual wellbeing in women with premature ovarian failure. Menopause 2008; 15: 23-31
16. Kalantaridou S N, Calis K A, Vanderhoof V H, et al. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2006; 86: 1475-82
17. Van Look P F, Lothian H, Hunter W M, Michie E A, Baird D T. Hypothalamic-pituitary-ovarian function in perimenopausal women. Clin Endocrinol 1977; 7: 13-31
18. Gold E B, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006; 96: 1226-35
19. Mishra G D, Kuh D. Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. BMJ 2012; 344: E402
20. Avis N E, Brockwell S, Randolph J F J r, et al. Longitudinal changes in sexual functioning as women transition through menopause: Results from the Study of Women's Health Across the Nation. Menopause 2009; 16: 442-52
21. Chuni N, Sreeramareddy CT. Frequency of symptoms, determinants of severe symptoms, validity of and cut-off score for Menopause Rating Scale (MRS) as a screening tool: A cross-sectional survey among midlife Nepalese women. BMC Women's Health 2011; 11: 30
22. Olaolorun F M, Lawoyin T O. Experience of menopausal symptoms by women in an urban community in Ibadan, Nigeria. Menopause 2009; 16: 822-30
23. Waidyasekera H, Wijewardena K, Lindmark G, Naessen T. Menopausal symptoms and quality of life during the menopausal transition in Sri Lankan women. Menopause 2009; 16: 164-70
24. Blumel JE, Chedraui P, Baron G, et al. Alarge multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-Aged women. Menopause 2011; 18: 778-85
25. Vikstrom J, Spetz Holm AC, Sydsjo G, Marcusson J, Wressle E, Hammar M. Hot flushes still occur in a population of 85-year-old Swedish women. Climacteric 2013; 16: 453-9
26. Kroenke C H, Caan B J, Stefanick M L, et al. Effects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative. Menopause 2012; 19: 980-8
27. Elavsky S, Gonzales J U, Proctor D N, Williams N, Henderson VW. Effects of physical activity on vasomotor symptoms: Examination using objective and subjective measures. Menopause 2012; 19: 1095-103
28. de Villiers T J, Gass M L, Haines C J, et al. Global Consensus Statement on menopausal hormone therapy. Climacteric 2013; 16: 203-4
29. Estrogen and progestogen use in peri-And postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168-82
30. Chrisman C, Ribeiro P, Dalton VK. The levonorgestrelreleasing intrauterine system: An updated review of the contraceptive and noncontraceptive uses. Clin Obstet Gynecol 2007; 50: 886-97
31. Simon JA. What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?. Menopause 2014; 21: 769-83
32. Fournier A, Fabre A, Mesrine S, Boutron-Ruault M C, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology-And hormone receptor-defined invasive breast cancer. J Clin Oncol 2008; 26: 1260-8
33. Leonetti H, Longo S, Anasti J. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999; 94: 225-8
34. Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen stimulated endometrium. Fertil Steril 2003; 79: 221-2
35. Cooper A, Spencer M I, Whitehead M, Ross D, Barnard GJR, Collins WP. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet 1998; 351: 1255
36. Birkhauser M H, Panay N, Archer D F, et al. Updated practical recommendations for hormone replacement therapy in the periand postmenopause. Climacteric 2008; 11: 108-23
37. Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: Results of a randomized active-controlled trial. J Sex Med 2008; 5: 646-56
38. Cummings S R, Ettinger B, Delmas P D, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697-708
39. Pinkerton JV, Abraham L, Bushmakin AG, et al. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective Estrogens, Menopause and Response to Therapy (SMART) Trials. J Womens Health (Larchmt) 2014; 23: 18-28
40. Mirkin S, Komm B S, Pan K, Chines A A. Effects of bazedoxifene/ conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013; 16: 338-46
41. de Villiers TJ, Chines AA, P alacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22: 567-76
42. Pinkerton JV, Komm BS, Mirkin S. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model. Climacteric 2013; 16: 618-28
43. Portman D J, Bachmann G A, Simon J A. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20: 623-30
44. Simon J, Portman D, Mabey R G J r. Long-Term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas 2014; 77: 274-81
45. Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: A systematic review and meta-Analysis of randomized trials. J Gen Intern Med 2014; 29: 204-13
46. Salmi T, Punnonen R. Clonidine in the treatment of menopausal symptoms. Int J Gynaecol Obstet 1979; 16: 422-6
47. Lindsay R, Hart D M. Failure of response of menopausal vasomotor symptoms to clonidine. Maturitas 1978; 1: 21-5
48. Bolli P, Simpson FO. Clonidine in menopausal flushing: A doubleblind trial. N Z Med J 1975; 82: 196-7
49. Pandya KJ, Raubertas RF, Flynn PJ, e t al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifeninduced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000; 132: 788-93
50. Lavigne J E, Heckler C, Mathews J L, et al. Arandomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors . Breast Cancer Res Treat 2012; 136: 479-86
51. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: A randomised doubleblind placebo-controlled trial. Lancet 2005; 366: 818-24
52. Nguyen M L. The use of pregabalin in the treatment of hot flashes. Can Pharm J 2013; 146: 193-6
53. E lkins G R, Fisher W I, Johnson A K, Carpenter J S, Keith T Z. Clinical hypnosis in the treatment of postmenopausal hot flashes: A randomized controlled trial. Menopause 2013; 20: 291-8
54. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): A randomised controlled trial. Lancet Oncol 2012; 13: 309-18
55. Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. Climacteric 2013; 16: 235-9
56. Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: A pilot study. Lancet Oncol 2008; 9: 523-32
57. Davis S R, Davison S L, Donath S, Bell R. Relationships between circulating androgen levels and self-reported sexual function in women. JAMA 2005; 294: 91-6
58. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226-33
59. Davis S R, Moreau M, Kroll R, et al. Testosterone for low libido in menopausal women not taking estrogen therapy. N Engl J Med 2008; 359: 2005-17
60. Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: The ADORE study. Climacteric 2010; 13: 121-31
61. Davis SR, Panjari M, Stanczyk FZ. DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 2011; 96: 1642-53
62. Alkatib AA, Cosma M, Elamin MB, et al. Asystematic review and meta-Analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 2009; 94: 3676-81